Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 206

1.

Initial immunoglobulin M 'flare' after rituximab therapy in patients diagnosed with Waldenstrom macroglobulinemia: an Eastern Cooperative Oncology Group Study.

Ghobrial IM, Fonseca R, Greipp PR, Blood E, Rue M, Vesole DH, Gertz MA; Eastern Cooperative Oncology Group.

Cancer. 2004 Dec 1;101(11):2593-8.

PMID:
15493038
[PubMed - indexed for MEDLINE]
Free Article
2.

Soluble CD27 is a faithful marker of disease burden and is unaffected by the rituximab-induced IgM flare, as well as by plasmapheresis, in patients with Waldenström's macroglobulinemia.

Ciccarelli BT, Yang G, Hatjiharissi E, Ioakimidis L, Patterson CJ, Manning RJ, Xu L, Liu X, Tseng H, Gong P, Sun J, Zhou Y, Treon SP.

Clin Lymphoma Myeloma. 2009 Mar;9(1):56-8. doi: 10.3816/CLM.2009.n.014.

PMID:
19362974
[PubMed - indexed for MEDLINE]
3.

Paradoxical increases in serum IgM and viscosity levels following rituximab in Waldenstrom's macroglobulinemia.

Treon SP, Branagan AR, Hunter Z, Santos D, Tournhilac O, Anderson KC.

Ann Oncol. 2004 Oct;15(10):1481-3.

PMID:
15367407
[PubMed - indexed for MEDLINE]
Free Article
4.

Extended rituximab therapy in Waldenström's macroglobulinemia.

Treon SP, Emmanouilides C, Kimby E, Kelliher A, Preffer F, Branagan AR, Anderson KC, Frankel SR; Waldenström's Macroglobulinemia Clinical Trials Group.

Ann Oncol. 2005 Jan;16(1):132-8.

PMID:
15598950
[PubMed - indexed for MEDLINE]
Free Article
5.

Treatment of Waldenström's macroglobulinemia with rituximab.

Dimopoulos MA, Zervas C, Zomas A, Kiamouris C, Viniou NA, Grigoraki V, Karkantaris C, Mitsouli C, Gika D, Christakis J, Anagnostopoulos N.

J Clin Oncol. 2002 May 1;20(9):2327-33.

PMID:
11981004
[PubMed - indexed for MEDLINE]
6.

CD20-directed antibody-mediated immunotherapy induces responses and facilitates hematologic recovery in patients with Waldenstrom's macroglobulinemia.

Treon SP, Agus TB, Link B, Rodrigues G, Molina A, Lacy MQ, Fisher DC, Emmanouilides C, Richards AI, Clark B, Lucas MS, Schlossman R, Schenkein D, Lin B, Kimby E, Anderson KC, Byrd JC.

J Immunother. 2001 May-Jun;24(3):272-9.

PMID:
11394506
[PubMed - indexed for MEDLINE]
7.

[Effective treatment with rituximab in two patients with Waldenström macroglobulinemia].

Yoshimi A, Arai S, Iijima K, Iki S, Usuki K, Urabe A.

Rinsho Ketsueki. 2005 Oct;46(10):1109-13. Japanese.

PMID:
16440772
[PubMed - indexed for MEDLINE]
8.

Clinical value of minor responses after 4 doses of rituximab in Waldenström macroglobulinaemia: a follow-up of the Eastern Cooperative Oncology Group E3A98 trial.

Gertz MA, Abonour R, Heffner LT, Greipp PR, Uno H, Rajkumar SV.

Br J Haematol. 2009 Dec;147(5):677-80. doi: 10.1111/j.1365-2141.2009.07892.x. Epub 2009 Sep 14.

PMID:
19751237
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

Multicenter phase 2 trial of rituximab for Waldenström macroglobulinemia (WM): an Eastern Cooperative Oncology Group Study (E3A98).

Gertz MA, Rue M, Blood E, Kaminer LS, Vesole DH, Greipp PR.

Leuk Lymphoma. 2004 Oct;45(10):2047-55.

PMID:
15370249
[PubMed - indexed for MEDLINE]
10.

Extended rituximab therapy for previously untreated patients with Waldenström's macroglobulinemia.

Dimopoulos MA, Zervas C, Zomas A, Hamilos G, Gika D, Efstathiou E, Panayiotidis P, Vervessou E, Anagnostopoulos N, Christakis J.

Clin Lymphoma. 2002 Dec;3(3):163-6.

PMID:
12521393
[PubMed - indexed for MEDLINE]
11.

Polymorphisms in FcgammaRIIIA (CD16) receptor expression are associated with clinical response to rituximab in Waldenström's macroglobulinemia.

Treon SP, Hansen M, Branagan AR, Verselis S, Emmanouilides C, Kimby E, Frankel SR, Touroutoglou N, Turnbull B, Anderson KC, Maloney DG, Fox EA.

J Clin Oncol. 2005 Jan 20;23(3):474-81.

PMID:
15659493
[PubMed - indexed for MEDLINE]
12.

Primary treatment of Waldenström macroglobulinemia with dexamethasone, rituximab, and cyclophosphamide.

Dimopoulos MA, Anagnostopoulos A, Kyrtsonis MC, Zervas K, Tsatalas C, Kokkinis G, Repoussis P, Symeonidis A, Delimpasi S, Katodritou E, Vervessou E, Michali E, Pouli A, Gika D, Vassou A, Terpos E, Anagnostopoulos N, Economopoulos T, Pangalis G.

J Clin Oncol. 2007 Aug 1;25(22):3344-9. Epub 2007 Jun 18.

PMID:
17577016
[PubMed - indexed for MEDLINE]
13.

Immunoglobulin M 'Flare' after rituximab-associated acute tubular necrosis in Waldenström's macroglobulinemia.

Izzedine H, Bourry E, Amrouche L, Brocheriou I, Uzunov M, Capron F, Leblond V, Deray G.

Int J Hematol. 2009 Mar;89(2):218-22. doi: 10.1007/s12185-008-0244-7. Epub 2009 Jan 21.

PMID:
19156501
[PubMed - indexed for MEDLINE]
14.

Lenalidomide and rituximab in Waldenstrom's macroglobulinemia.

Treon SP, Soumerai JD, Branagan AR, Hunter ZR, Patterson CJ, Ioakimidis L, Chu L, Musto P, Baron AD, Nunnink JC, Kash JJ, Terjanian TO, Hyman PM, Nawfel EL, Sharon DJ, Munshi NC, Anderson KC.

Clin Cancer Res. 2009 Jan 1;15(1):355-60. doi: 10.1158/1078-0432.CCR-08-0862.

PMID:
19118065
[PubMed - indexed for MEDLINE]
Free Article
15.

Activity of fludarabine in previously treated Waldenström's macroglobulinemia: a report of 71 cases. Groupe Coopératif Macroglobulinémie.

Leblond V, Ben-Othman T, Deconinck E, Taksin AL, Harousseau JL, Delgado MA, Delmer A, Maloisel F, Mariette X, Morel P, Clauvel JP, Duboisset P, Entezam S, Hermine O, Merlet M, Yakoub-Agha I, Guibon O, Caspard H, Fort N.

J Clin Oncol. 1998 Jun;16(6):2060-4.

PMID:
9626204
[PubMed - indexed for MEDLINE]
16.

Primary therapy of Waldenstrom macroglobulinemia (WM) with weekly bortezomib, low-dose dexamethasone, and rituximab (BDR): long-term results of a phase 2 study of the European Myeloma Network (EMN).

Dimopoulos MA, García-Sanz R, Gavriatopoulou M, Morel P, Kyrtsonis MC, Michalis E, Kartasis Z, Leleu X, Palladini G, Tedeschi A, Gika D, Merlini G, Kastritis E, Sonneveld P.

Blood. 2013 Nov 7;122(19):3276-82. doi: 10.1182/blood-2013-05-503862. Epub 2013 Sep 4.

PMID:
24004667
[PubMed - indexed for MEDLINE]
17.

Waldenström macroglobulinemia.

Vijay A, Gertz MA.

Blood. 2007 Jun 15;109(12):5096-103. Epub 2007 Feb 15. Review.

PMID:
17303694
[PubMed - indexed for MEDLINE]
Free Article
18.

Predictive factors for response to rituximab in Waldenstrom's macroglobulinemia.

Dimopoulos MA, Anagnostopoulos A, Zervas C, Kyrtsonis MC, Zomas A, Bourantas C, Anagnostopoulos N, Pangalis G.

Clin Lymphoma. 2005 Mar;5(4):270-2.

PMID:
15794863
[PubMed - indexed for MEDLINE]
19.

Rituximab therapy in Waldenstrom's macroglobulinemia: preliminary evidence of clinical activity.

Byrd JC, White CA, Link B, Lucas MS, Velasquez WS, Rosenberg J, Grillo-López AJ.

Ann Oncol. 1999 Dec;10(12):1525-7.

PMID:
10643548
[PubMed - indexed for MEDLINE]
Free Article
20.

Treatment of Waldenstrom's macroglobulinemia with rituximab: prognostic factors for response and progression.

Dimopoulos MA, Alexanian R, Gika D, Anagnostopoulos A, Zervas C, Zomas A, Kyrtsonis MC, Anagnostopoulos N, Pangalis GA, Weber DM.

Leuk Lymphoma. 2004 Oct;45(10):2057-61.

PMID:
15370250
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk